Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zilongjin is a traditional Chinese medicine (TCM) compound preparation formulated as a tablet and used primarily as an adjunct therapy for cancer patients, especially those with primary lung cancer experiencing "qi" and "blood" deficiency syndromes during chemotherapy[1][4][8]. It consists of eight herbal ingredients including Astragalus membranaceus (Radix astragali), Angelica sinensis (Chinese angelica), Herba Solani lyrati (Lyrate nightshade), Herba Solani nigra (Long kui cao), Salvia miltiorrhizae radix et rhizoma, and Scutellaria barbatae herba[3][5]. The formulation is designed to support the immune system, alleviate chemotherapy-induced toxicity such as leukopenia and organ damage, improve clinical symptoms, and potentially inhibit tumor growth[2][3][9]. Mechanistic studies suggest that it may exert anti-cancer effects by modulating gene expression related to apoptosis, cell cycle regulation, and MAPK signaling pathways in tumor cells[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zilongjin.